专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009027909A2 APPARATUS AND METHOD FOR MANAGING ACCESS TO ONE OR MORE NETWORK RESOURCES 审中-公开
标题翻译：用于管理对一个或多个网络资源的访问的装置和方法
公开(公告)号：WO2009027909A2
公开(公告)日：2009-03-05
申请号：PCT/IB2008/053360
申请日：2008-08-21
申请人： NOKIA CORPORATION , KALOFONOS, Dimitris , REYNOLDS, Franklin
发明人： KALOFONOS, Dimitris , REYNOLDS, Franklin
CPC分类号： H04L63/0227 , H04L63/102
摘要： An apparatus is provided that includes a processor configured to receive a captured traffic unit (CTU) intended for a network service, the CTU being one into which incoming traffic has been assembled based on a filter describing which incoming traffic to capture and how to assemble the respective incoming traffic into the CTU. The processor is also configured to determine whether to allow the CTU to pass to one or more applications configured to implement the respective network service based on a passlet including permissions to a particular user. The processor is further configured to instruct a firewall to allow the CTU to pass to the respective one or more applications or to reject the CTU based on the determination. In this regard, the processor is configured to perform the above functions under control of a security framework implemented in middleware between a user-level domain and a system-level domain.
摘要翻译：提供了一种设备，其包括处理器，该处理器被配置为接收旨在用于网络服务的捕获的流量单元（CTU），所述CTU是基于描述哪个入站要捕获的流量以及如何将相应的流量汇集到CTU中。处理器还被配置为基于包括对特定用户的许可的小圆确定是否允许CTU传递到被配置为实现相应网络服务的一个或多个应用。处理器还被配置为指示防火墙允许CTU基于该确定传递给相应的一个或多个应用或拒绝CTU。就此而言，处理器被配置为在用户级域和系统级域之间的中间件中实施的安全框架的控制下执行上述功能。

2. 发明申请

WO2006134476A1 MANAGEMENT OF ACCESS CONTROL IN WIRELESS NETWORKS 审中-公开
标题翻译：无线网络中访问控制管理
公开(公告)号：WO2006134476A1
公开(公告)日：2006-12-21
申请号：PCT/IB2006/001595
申请日：2006-06-14
申请人： NOKIA CORPORATION , KALOFONOS, Dimitris , SHAKHSHIR, Saad
发明人： KALOFONOS, Dimitris , SHAKHSHIR, Saad
IPC分类号： G06F21/00 , H04L29/06 , H04L9/32
CPC分类号： H04L63/0428 , H04L12/2803 , H04L12/282 , H04L63/101 , H04L63/102 , H04L2012/285 , H04W12/08
摘要： Management of access control in wireless networks known as smart spaces includes a framework that presents non-expert users with a consistent and intuitive interaction mechanism to manage access to devices they own in the smart space without exposing to them the complexity of the underlying security infrastructure. Access control of devices in a network can include providing an interface between a user-level tool on a first device connected to a network and security components associated with the network, communicating a passlet between the user-level tool and the interface, verifying access permission at a second device on the network where access permissions are based on the passlet, and providing a response to the first device based on the verification of the access permission in the passlet. The passlet provides access permissions based on a particular user rather than a particular device.
摘要翻译：在被称为智能空间的无线网络中的访问控制管理包括一个框架，为非专家用户提供一致和直观的交互机制，以管理他们在智能空间中拥有的设备的访问，而不会暴露底层安全基础架构的复杂性。网络中设备的访问控制可以包括在连接到网络的第一设备上的用户级工具与与网络相关联的安全组件之间提供接口，在用户级工具和接口之间传递密码，验证访问权限在网络上的第二设备上，其中访问权限基于该密码，并且基于该密码中的访问许可的验证来向第一设备提供响应。该邮袋提供基于特定用户而不是特定设备的访问权限。

3. 发明申请

WO2006021847A1 SYSTEM AND METHOD FOR MANAGING A WIRELESS CONNECTION TO REDUCE POWER CONSUMPTION OF A MOBILE TERMINAL 审中-公开
标题翻译：用于管理无线连接以减少移动终端的功耗的系统和方法
公开(公告)号：WO2006021847A1
公开(公告)日：2006-03-02
申请号：PCT/IB2005/002254
申请日：2005-07-28
申请人： NOKIA CORPORATION , KALOFONOS, Dimitris , SAARANEN, Mika , STIRBU, Vlad , CHAN, Cathy
发明人： KALOFONOS, Dimitris , SAARANEN, Mika , STIRBU, Vlad , CHAN, Cathy
IPC分类号： H04Q7/32 , H04L12/28
CPC分类号： H04W52/0212 , H04L12/189 , H04W28/10 , H04W76/27 , H04W84/18 , H04W88/08 , H04W92/10 , Y02D70/1222 , Y02D70/1224 , Y02D70/1242 , Y02D70/142 , Y02D70/144
摘要： A mobile terminal includes a processor capable of operating a link manager. The link manager is capable of at least partially operating a wireless connection between the terminal and an access point in an active mode, where the access point is coupled to a network. The link manager is also capable of transitioning the connection from the active mode to a standby mode or hibernate mode. In this regard, transitioning the connection includes entering the mobile terminal in a power-saving mode of a bearer of the connection, such as a Bluetooth power-saving mode, and directing the access point to reduce traffic flowing from the network across the connection to the mobile terminal when the mobile terminal is otherwise capable of receiving the traffic.
摘要翻译：移动终端包括能够操作链路管理器的处理器。链路管理器能够至少部分地在主动模式下操作终端和接入点之间的无线连接，其中接入点耦合到网络。链接管理器还能够将连接从活动模式转换到待机模式或休眠模式。在这方面，转换连接包括以诸如蓝牙功率节省模式的连接承载的功率节省模式进入移动终端，并且引导接入点减少通过该连接从网络流动的业务到移动终端当移动终端另外能够接收业务时。

4. 发明申请

WO2006013446A1 SYSTEMS, NODES, AND METHODS FOR DYNAMIC END-TO-END SESSION-ENHANCING SERVICES FOR TRANSPORT-LEVEL-BASED CONNECTIONS 审中-公开
标题翻译：用于基于运输级连接的动态终端会话增强服务的系统，节点和方法
公开(公告)号：WO2006013446A1
公开(公告)日：2006-02-09
申请号：PCT/IB2005/002251
申请日：2005-07-25
申请人： NOKIA CORPORATION , KALOFONOS, Dimitris , SHAH, Parijat
发明人： KALOFONOS, Dimitris , SHAH, Parijat
IPC分类号： H04L29/06
CPC分类号： H04L67/16 , H04L69/16 , H04L69/162 , H04L69/163 , H04L69/24 , H04W80/04 , H04W80/10
摘要： Provided are improved systems, nodes, and methods for enabling dynamic end-to-end (e2e) session-enhancing services for transport-level connections such as TCP-based connection sessions, thereby providing the communicating entities the ability to select, adjust, and control e2e session enhancing (e2e-SE) services before and during communications. Embodiments allow for dynamic negotiation and renegotiations of e2e session-enhancing services at establishment of and during the active course of communication sessions, such as at establishment of and during transparent e2e-SE services TCP connections. Embodiments may be used as part of any e2e session-enhancing services frame work for mobile or wireless and wireline communications. End-to-end session-enhancing services can be dynamically added and removed according to the need of applications and existing and changing conditions without affecting the on-going communication and the applications running on both end nodes.
摘要翻译：提供了用于为诸如基于TCP的连接会话之类的传输级连接启用动态端到端（e2e）会话增强服务的改进的系统，节点和方法，从而为通信实体提供选择，调整和在通信之前和期间控制e2e会话增强（e2e-SE）服务。实施例允许在通信会话的主动过程中和期间，例如在建立和透明的e2e-SE服务TCP连接期间以及期间在e2e会话增强服务的动态协商和重新协商。实施例可以用作用于移动或无线和有线通信的任何e2e会话增强服务帧工作的一部分。端到端会话增强服务可以根据应用程序的需要和现有和变化的条件动态添加和删除，而不会影响正在进行的通信和在两端节点上运行的应用程序。

5. 发明申请

WO2010017343A2 FLUPIRTINE HYDROCHLORIDE MALEIC ACID COCRYSTAL 审中-公开
标题翻译： FLUPIRTINE氢氯酸盐马来酸盐
公开(公告)号：WO2010017343A2
公开(公告)日：2010-02-11
申请号：PCT/US2009/052925
申请日：2009-08-06
申请人： BIONEVIA PHARMACEUTICALS, INC. , KALOFONOS, Isabel , STAHLY, G., Patrick , MARTIN-DOYLE, William , KALOFONOS, Dimitris , STULTS, Jeffrey, S. , HANKO, Jason, A. , SHIPPLETT, Rex, A.
发明人： KALOFONOS, Isabel , STAHLY, G., Patrick , MARTIN-DOYLE, William , KALOFONOS, Dimitris , STULTS, Jeffrey, S. , HANKO, Jason, A. , SHIPPLETT, Rex, A.
IPC分类号： C07D213/75 , A61K31/44 , A61P25/04 , A61P25/00 , C07D211/36
CPC分类号： C07D213/75
摘要： The invention relates to crystalline forms of flupirtine, particularly to 1:1 flupirtine hydrochloride maleic acid cocrystal. The preparation and characterization of 1:1 flupirtine hydrochloride maleic acid cocrystal is described. The invention also relates to the therapeutic use of the flupirtine hydrochloride maleic acid cocrystal to treat nervous system disorders, pain disorders, and musculoskeletal disorders and to pharmaceutical compositions containing the cocrystal.
摘要翻译：本发明涉及氟吡汀的结晶形式，特别涉及1：1盐酸氟吡汀马来酸共结晶。描述了1：1盐酸氟吡汀马来酸共晶体的制备和表征。本发明还涉及氟吡汀盐酸马来酸共结晶治疗神经系统疾病，疼痛障碍和肌肉骨骼疾病以及含有共晶体的药物组合物的治疗用途。

6. 发明申请

WO2010011922A2 NOVEL CRYSTALLINE SALTS OF EPALRESTAT 审中-公开
标题翻译： EPALRESTAT的新型结晶盐
公开(公告)号：WO2010011922A2
公开(公告)日：2010-01-28
申请号：PCT/US2009/051687
申请日：2009-07-24
申请人： BIONEVIA PHARMACEUTICALS, INC. , KALOFONOS, Isabel , STAHLY, G., Patrick , MARTIN-DOYLE, William , KALOFONOS, Dimitris , STULTS, Jeffrey, S. , HOUSTON, Travis, L.
发明人： KALOFONOS, Isabel , STAHLY, G., Patrick , MARTIN-DOYLE, William , KALOFONOS, Dimitris , STULTS, Jeffrey, S. , HOUSTON, Travis, L.
IPC分类号： C07D277/36 , C07D277/593 , C07F1/06 , A61K31/41 , A61K31/42 , A61P3/10
CPC分类号： C07D277/36 , A61K31/41 , A61K31/42
摘要： The invention relates to novel crystalline salts of 5-[(lZ,2E)-2-methyl-3- phenyIpropenylidene]-4-oxo-2-thioxo-3-thiazolidineaeetic acid. The preparation and characterization of the crystalline salts according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and the therapeutic use of the novel crystalline salts to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic.
摘要翻译：本发明涉及5 - [（1Z，2E）-2-甲基-3-苯基亚丙叉基] -4-氧代-2-硫代-3-噻唑烷酮酸的新结晶盐。描述根据本发明的各种实施方案的结晶盐的制备和表征。本发明还涉及含有新型结晶盐的新型结晶盐和治疗和/或预防各种病症的治疗用途的药物组合物，包括治疗和/或预防糖尿病并发症，抑制醛糖还原酶，以及在患者中提供心脏保护非糖尿病

7. 发明申请

WO2010081070A2 NOVEL FORMS OF EPERISONE 审中-公开
标题翻译： EPERISONE的新形式
公开(公告)号：WO2010081070A2
公开(公告)日：2010-07-15
申请号：PCT/US2010/020614
申请日：2010-01-11
申请人： BIONEVIA PHARMACEUTICALS, INC. , KALOFONOS, Isabel , STAHLY, G., Patrick , MARTIN-DOYLE, William , KALOFONOS, Dimitris , STULTS, Jeffrey, S. , HANKO, Jason, A.
发明人： KALOFONOS, Isabel , STAHLY, G., Patrick , MARTIN-DOYLE, William , KALOFONOS, Dimitris , STULTS, Jeffrey, S. , HANKO, Jason, A.
IPC分类号： C07D211/34 , A61K31/445 , A61P21/02
CPC分类号： C07D295/108 , A61K31/445
摘要： The invention relates to novel crystalline forms of (2RS)-1 -(4-ethylphenyl)-2-methyl-3- piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotonic conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension.
摘要翻译：本发明涉及（2RS）-1-（4-乙基苯基）-2-甲基-3-哌啶-1-基 - 丙-1-酮的新结晶形式。描述根据本发明的各种实施方案的新型结晶形式的制备和表征。本发明还涉及含有新型结晶形式的药物组合物，其可用于治疗和/或预防各种病症如病理性肌肉挛缩，强直条件和由各种神经病症引起的痉挛性麻痹或痉挛状态，并且还可用于治疗和/或预防各种类型的疼痛和病理性肌肉紧张。

8. 发明申请

WO2010028132A3 NOVEL CHOLINE COCRYSTAL OF EPALRESTAT 审中-公开
公开(公告)号：WO2010028132A3
公开(公告)日：2010-03-11
申请号：PCT/US2009/055868
申请日：2009-09-03
申请人： BIONEVIA PHARMACEUTICALS, INC. , KALOFONOS, Isabel , STAHLY, G., Patrick , MARTIN-DOYLE, William , KALOFONOS, Dimitris , STULTS, Jeffrey, S. , HOUSTON, Travis, L.
发明人： KALOFONOS, Isabel , STAHLY, G., Patrick , MARTIN-DOYLE, William , KALOFONOS, Dimitris , STULTS, Jeffrey, S. , HOUSTON, Travis, L.
IPC分类号： C07D277/36 , C07D277/32 , A61K31/19 , A61P3/10
摘要： The invention relates to a novel choline cocrystal of 5-[(lZ.2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.

9. 发明申请

WO2010017135A2 NOVEL FORMS OF EPERISONE 审中-公开
标题翻译：新型EPERISONE
公开(公告)号：WO2010017135A2
公开(公告)日：2010-02-11
申请号：PCT/US2009/052575
申请日：2009-08-03
申请人： BIONEVIA PHARMACEUTICALS, INC. , KALOFONOS, Isabel , STAHLY, G., Patrick , MARTIN-DOYLE, William , KALOFONOS, Dimitris , HANKO, Jason, A. , STULTS, Jeffrey, S. , KIPLINGER, Jeffrey, P.
发明人： KALOFONOS, Isabel , STAHLY, G., Patrick , MARTIN-DOYLE, William , KALOFONOS, Dimitris , HANKO, Jason, A. , STULTS, Jeffrey, S. , KIPLINGER, Jeffrey, P.
IPC分类号： C07D211/34 , A61K31/445 , A61P21/02
CPC分类号： C07D295/108
摘要： The invention relates to substantially enantiopure crystalline salt forms of (2RS)-I -(4- Ethylphenyl)-2-methyl-3-piperidin-l-ylpropan-l-one. The preparation and characterization of the substantially enantiopure crystalline salt forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the substantially enantiopure crystalline salt forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotome conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension.
摘要翻译：本发明涉及（2RS）-1-（4-乙基苯基）-2-甲基-3-哌啶-1-基丙-1-酮的基本上对映体纯的晶体盐形式。描述了根据本发明的各种实施方式的基本上对映异构纯的结晶盐形式的制备和表征。本发明还涉及含有基本上对映体纯的结晶盐形式的药物组合物，其可用于治疗和/或预防各种病症，例如由各种神经病症引起的病理性肌肉挛缩，肌肉瘤症状和痉挛性瘫痪或痉挛，并且也是有用的用于治疗和/或预防各种类型的疼痛和病理性肌肉紧张。

10. 发明申请

WO2010011926A2 A NOVEL BETAINE COCRYSTAL OF EPALRESTAT 审中-公开
标题翻译： EPALRESTAT的新型BETAINE COCRYSTAL
公开(公告)号：WO2010011926A2
公开(公告)日：2010-01-28
申请号：PCT/US2009/051693
申请日：2009-07-24
申请人： BIONEVIA PHARMACEUTICALS, INC. , KALOFONOS, Isabel , STAHLY, Patrick, G. , MARTIN-DOYLE, William , KALOFONOS, Dimitris , STULTS, Jeffrey, S. , HOUSTON, Travis, L.
发明人： KALOFONOS, Isabel , STAHLY, Patrick, G. , MARTIN-DOYLE, William , KALOFONOS, Dimitris , STULTS, Jeffrey, S. , HOUSTON, Travis, L.
IPC分类号： C07D277/36 , A61K31/25 , A61K31/20 , A61P3/10
CPC分类号： A61K31/20 , A61K31/25 , C07D277/36
摘要： The invention relates to a novel betaine cocrystal of 5-[(lZ,2E)-2-methyl-3- phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel betaine cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel betaine cocrystal and the therapeutic use of the novel betaine cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria, reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.
摘要翻译：本发明涉及5 - [（1Z，2E）-2-甲基-3-苯基亚丙基] -4-氧代-2-硫代-3-噻唑烷乙酸的新型甜菜碱共结晶。描述了根据本发明的各种实施方案的新型甜菜碱共晶体的制备和表征。本发明还涉及含有新颖的甜菜碱共晶体的药物组合物和新颖的甜菜碱共晶体用于治疗和/或预防各种病症的治疗用途，包括治疗和/或预防糖尿病并发症，治疗和/或预防同型胱尿蛋白尿，降低同型半胱氨酸的水平在血清中抑制醛糖还原酶，并在非糖尿病患者中提供心脏保护作用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式